^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
Source:
Title:
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study
Published date:
10/16/2023
Excerpt:
In summary, the BRCA2 cohort consists of 11 patients with adenocarcinoma of the pancreas and 16 patients with other tumor histology. The CBR is also similar between the two groups: 54.5% (three PR, three SD) and 43.8% (one CR, two PR and four SD). The responders were diagnosed with colon cancer, parathyroid carcinoma and pancreatic neuroendocrine carcinoma....In BRCA1/2-mutated cancers, olaparib can be active and produce durable responses in various cancer types.
Trial ID:
Source:
Title:
152P - Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study
Published date:
10/16/2023
Excerpt:
Open-label multi-cohort phase 2 study that examines the efficacy of olaparib in patients with an HR gene mutation in their tumor and failed SoC….One patient with a BRCA2 germline mutated colon cancer has an ongoing CR with 19+ months on treatment….